BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 781579)

  • 1. BCG immunotherapy of a mucous membrane malignant melanoma. Report of a case.
    Pliskin ME; Mastrangelo MJ; Bellet R; Berkelhammer J
    Oral Surg Oral Med Oral Pathol; 1976 Jul; 42(1):73-9. PubMed ID: 781579
    [No Abstract]   [Full Text] [Related]  

  • 2. [Multidisciplinary treatment of malignant melanoma of the nose and paranasal sinuses--with special reference to oral administration of enterosoluble BCG capsules].
    Saito H; Hozawa J; Takagi A; Fukuoka K; Nozawa I; Kamimura T
    Gan To Kagaku Ryoho; 1982 Sep; 9(9):1555-61. PubMed ID: 6191718
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [BCG immunotherapy for malignant melanoma of the nose and paranasal sinuses (author's transl)].
    Saito H; Hozawa J; Kasahara M; Takagi A; Nagai M
    Nihon Jibiinkoka Gakkai Kaiho; 1980 Jun; 83(6):647-53. PubMed ID: 7463195
    [No Abstract]   [Full Text] [Related]  

  • 4. Immunoprophylaxis of malignant melanoma with systemic BCG: study of strain, dose, and schedule.
    Gutterman JU; Mavligit G; McBride C; Frei E; Hersh EM
    Natl Cancer Inst Monogr; 1973 Dec; 39():205-12. PubMed ID: 4595319
    [No Abstract]   [Full Text] [Related]  

  • 5. Mucosal melanoma. Immunological findings in a rare case treated with BCG vaccine, autologous tumor cells, and cytarabine.
    Edström S; Jacobsson S; Jeppsson PH
    Arch Otolaryngol; 1979 Jan; 105(1):48-50. PubMed ID: 760707
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of melanoma of nose and paranasal sinuses.
    Walker EA; Snow JB
    Arch Otolaryngol; 1969 Apr; 89(4):652-60. PubMed ID: 5766758
    [No Abstract]   [Full Text] [Related]  

  • 7. Immunotherapy of human malignant melanoma with oil-attached BCG cell-wall skeleton.
    Yamamura Y; Yoshizaki K; Azuma I; Yagura T; Watanabe T
    Gan; 1975 Aug; 66(4):355-63. PubMed ID: 1102379
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Results of administering B.C.G. to patients with melanoma.
    Grant RM; Mackie R; Cochran AJ; Murray EL; Hoyle D; Ross C
    Lancet; 1974 Nov; 2(7889):1096-100. PubMed ID: 4139404
    [No Abstract]   [Full Text] [Related]  

  • 9. In vitro monitoring of cellular function during BCG immunotherapy.
    Golub SH; Roth JA; Forsythe A; Morton DL
    Bibl Haematol; 1975 Oct; (43):270-3. PubMed ID: 786261
    [No Abstract]   [Full Text] [Related]  

  • 10. Malignant melanoma.
    Spitler LE
    J Invest Dermatol; 1976 Sep; 67(3):435-41. PubMed ID: 787436
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and histologic correlation of melanoma regression after intralesional BCG therapy: a case report.
    Mastrangelo MJ; Kim YH; Bornstein RS; Chee DO; Sulit HL; Yarbro JW; Prehn RT
    J Natl Cancer Inst; 1974 Jan; 52(1):19-24. PubMed ID: 4590009
    [No Abstract]   [Full Text] [Related]  

  • 12. [Mucous nasosinus melanoma. Apropos of a case].
    Medina Banegas A; Osete Albaladejo JM; González Ortin M; Martínez Silla G; Arcas Martínez-Jalos I
    Acta Otorrinolaringol Esp; 1989; 40(5):365-7. PubMed ID: 2631901
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcome of sinonasal melanoma: clinical experience and review of the literature.
    Roth TN; Gengler C; Huber GF; Holzmann D
    Head Neck; 2010 Oct; 32(10):1385-92. PubMed ID: 20146340
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro assay of cell-mediated immunity in BCG therapy of malignant melanoma: a preliminary report.
    Nathanson L; Clark DA
    Natl Cancer Inst Monogr; 1973 Dec; 39():221-4. PubMed ID: 4595321
    [No Abstract]   [Full Text] [Related]  

  • 15. Melanoma of the nasal and paranasal sinus mucosa.
    Trapp TK; Fu YS; Calcaterra TC
    Arch Otolaryngol Head Neck Surg; 1987 Oct; 113(10):1086-9. PubMed ID: 3620131
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Case of a rare primary ectopic meningioma of the nose and maxillary sinus in a child].
    Stanisavljevic B; Stefanovic P; Pejcic M; Djordjevic M
    Rev Laryngol Otol Rhinol (Bord); 1975; 96(1-2):81-4. PubMed ID: 1144963
    [No Abstract]   [Full Text] [Related]  

  • 17. Specific cytotoxic antibody in the sera of patients with melanoma.
    Kilpatrick RJ; Seigler HF
    J Surg Res; 1976 Nov; 21(5):301-5. PubMed ID: 794584
    [No Abstract]   [Full Text] [Related]  

  • 18. Experience with BCG adjuvant immunotherapy in stage II malignant melanoma.
    Peter HH; Deutschmann EM; Schultheis W; Deicher H
    Dev Biol Stand; 1977 Apr 13-15; 38():537-40. PubMed ID: 344106
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Malignant melanomas of the nasal cavity and paranasal sinuses].
    Dreher A; Grevers G
    Laryngorhinootologie; 1995 Feb; 74(2):95-7. PubMed ID: 7710613
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mucosal melanomas of the head and neck.
    Snow GB; van der Waal I
    Otolaryngol Clin North Am; 1986 Aug; 19(3):537-47. PubMed ID: 3748582
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.